

Catalent Pharma Solutions Investor's Q4 Conference Call

Matthew Walsh
Chief Financial Officer
Catalent Pharma Solutions

September 25, 2009

Reliable Solutions. Inspired Results.™



Disclaimer Statement

Forward Looking Statements

This presentation and release contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate”, “intend”, “estimate”, “plan”, “project”, “foresee”, “likely”, “may”, “will”, “would” or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent Pharma Solutions’ expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: general industry conditions and competition; product or other liability risk inherent in the design, development, manufacture and marketing of our offerings; inability to enhance our existing or introduce new technology or services in a timely manner; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; and our substantial debt and debt service requirements that restrict our operating and financial flexibility and impose significant interest and financial costs. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission on September 29, 2008. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent Pharma Solutions does not undertake to update any forward- looking statements as a result of new information or future events or developments unless required by law.

Non-GAAP Financial Matters

In addition to disclosing financial results that are determined in accordance with US GAAP, Catalent discloses EBITDA and Adjusted EBITDA, which are non-GAAP measures. You should not consider EBITDA or Adjusted EBITDA as an alternative to operating or net earnings, determined in accordance with US GAAP, as an indicator of Catalent's operating performance, or as an alternative to cash flows from operating activities, determined in accordance with US GAAP, as an indicator of cash flows, or as a measure of liquidity. EBITDA is calculated by the sum of earnings before interest, taxes, depreciation and amortization.

The Company's credit facilities and the indentures governing the outstanding notes have certain covenants that use ratios utilizing a measure referred to as Adjusted EBITDA. The supplementary adjustments to EBITDA to derive Adjusted EBITDA may not be in accordance with current SEC practices or the rules and regulations adopted by the SEC that apply to periodic reports filed under the Securities Exchange Act of 1934. Accordingly, the SEC may require that Adjusted EBITDA be presented differently in filings that may be made with the SEC than as presented in this presentation and release, or not be presented at all. The most directly comparable US GAAP measure to EBITDA and Adjusted EBITDA is income/(loss) from continuing operations. Included in this release is a reconciliation of income/(loss) from continuing operations to EBITDA and to Adjusted EBITDA.

Agenda

- Fourth Quarter Highlights
- Business Update
- Q4 and Full-Year Financial Performance
- Adjusted EBITDA
- Cash Flow
- Q&A

Fourth Quarter Highlights

- Positive trend in sequential quarterly performance; year-over-year shortfall mostly driven by FX translation
- Focus on controllable spending (SG&A, capex, W/C)
- Cash flow for Q4 exceeded management expectations; \$43M revolver paydown
- **Oral Technologies**: Zydis[®] capacity utilization improved; growth in Rx softgel and solid-dose controlled release
- **Packaging Services**: continuing to align fixed costs to current volumes in North America; Europe ahead of prior year
- **Sterile Technologies**: analytical science services and blow-fill-seal down; continued growth in sterile injectables

Business Update – Oral Technologies

- Rx softgel business continues to perform ahead of expectations, with strong demand for several high-volume brand products in the US and Europe
- Successful audit of Buenos Aires softgel facility by US FDA with no Form 483 observations; significant expansion program underway... increases global supply flexibility
- Sales of nutritional and certain other consumer health softgel products remains weak due to low consumer demand in most markets
- Solid tablet dose manufacturing at Winchester facility – 30% profitability increase year-over-year
- Zydis operating performance returned to expected levels; sales and profitability flat to prior year

Business Update – Sterile Technologies

- Blow-fill-seal fourth quarter performance down significantly versus prior year due to product mix shift to lower margin generic products and operating efficiency/productivity shortfalls
- Analytical science services saw customers continuing to delay/cancel projects due to reduced budgets for development spending; our cost containment measures are continuing
- Sterile injectables profitability continues to incrementally improve; FDA product approval at Brussels PFS facility will help to grow an already strong pipeline of opportunities. Brussels up 14% over prior year

Business Update – Packaging Services

- US Commercial Packaging: Continued revenue pressures; cost reduction measures and efficiency gains through the BIDX (Lean) process – EBITDA off marginally vs. prior year
- US Printed Components: Continued work on aligning capacity to existing volumes; Pennsauken closure and Moorestown expansion proceeding as planned
- Clinical Services: Results level with prior year as stronger European volumes offset shortfalls in the US, where customers continue to delay/cancel clinical trial activity

FY2009 Q4 by Segment

(\$ millions)	Three Months	Three Months	Increase/(Decrease)		Excluding FX		
	Ended	Ended			Increase/(Decrease)		
	June 30, 2009	June 30, 2008	\$	%	\$	%	
Oral Technologies							
Net Revenue	253.5	285.4	(31.9)	-11.2%	0.5	0.2%	
Segment EBITDA	61.4	70.5	(9.1)	-12.9%	(2.0)	-2.9%	
Sterile Technologies							
Net Revenue	61.8	77.8	(16.1)	-20.7%	(12.7)	-16.3%	
Segment EBITDA	5.1	14.9	(9.8)	-65.7%	(9.7)	-64.9%	
Packaging Services							
Net Revenue	104.8	120.6	(15.8)	-13.1%	(5.6)	-4.6%	
Segment EBITDA	5.8	10.0	(4.2)	-42.2%	(2.5)	-24.7%	
Revenue Elimination	(10.2)	(13.7)	3.5	-25.7%	2.8	-20.6%	
Other EBITDA	11.1	(320.1)	331.2	*	320.0	*	
Combined Total							
Net Revenue	409.9	470.1	(60.2)	-12.8%	(15.0)	-3.2%	
EBITDA	83.4	(224.7)	308.1	*	305.9	*	
(from continuing operations)							

* % not meaningful



FY2009 Full-Year by Segment

(\$ millions)	Twelve Months	Twelve Months	Increase/(Decrease)		Excluding FX	
	Ended	Ended			Increase/(Decrease)	
	June 30, 2009	June 30, 2008	\$	%	\$	%
Oral Technologies						
Net Revenue	956.7	1,039.0	(82.3)	-7.9%	0.4	0.0%
Segment EBITDA	214.8	229.4	(14.6)	-6.4%	3.0	1.3%
Sterile Technologies						
Net Revenue	278.5	293.5	(15.0)	-5.1%	(7.6)	-2.6%
Segment EBITDA	27.5	40.7	(13.2)	-32.5%	(13.5)	-33.0%
Packaging Services						
Net Revenue	451.4	531.3	(79.9)	-15.0%	(49.9)	-9.4%
Segment EBITDA	28.4	61.9	(33.5)	-54.1%	(27.8)	-45.0%
Revenue Elimination	(47.1)	(46.1)	(1.0)	2.2%	(1.8)	3.9%
Other EBITDA	(207.8)	(510.1)	302.3	-59.3%	270.3	*
Combined Total						
Net Revenue	1,639.5	1,817.7	(178.2)	-9.8%	(59.0)	-3.2%
EBITDA	62.9	(178.1)	241.0	*	232.0	*
(from continuing operations)						

* % not meaningful



Operating Earnings to EBITDA

(\$ Millions)	Quarters Ended				LTM	Quarter Ended	LTM
	Jun 30, 2008	Sep 30, 2008	Dec 31, 2008	Mar 31, 2009	Mar 31, 2009	Jun 30, 2009	Jun 30, 2009
Income / (Loss) from continuing operations	(318.9)	21.8	(96.2)	(193.9)	(587.2)	(4.6)	(272.9)
Interest Expense, net	48.2	48.3	49.9	42.0	188.4	41.4	181.6
Income tax benefit	10.2	(7.3)	6.9	3.8	13.6	13.4	16.8
Depreciation and Amortization	35.8	38.2	37.8	28.1	139.9	33.3	137.4
EBITDA	(224.7)	101.0	(1.6)	(120.0)	(245.3)	83.5	62.9

LTM EBITDA Adjustments

(\$ millions)	Quarters Ended				LTM Mar 31, 2009	Quarter	LTM
	Jun 30, 2008	Sep 30, 2008	Dec 31, 2008	Mar 31, 2009		Ended Jun 30, 2009	Jun 30, 2009
EBITDA	(224.7)	101.0	(1.6)	(120.0)	(245.3)	83.5	62.9
FAS 123R Equity Expense	1.2	1.4	1.0	0.3	3.8	(2.9)	(0.3)
Impairment charges and (gain)/loss on sale of assets	316.6	0.1	(0.1)	192.6	509.1	2.7	195.2
Restructuring and other special items	3.0	2.6	1.9	7.7	15.2	8.0	20.2
Other non-recurring/one time items (Sterile Facility Start Up, non cash adjustments)	(1.7)	3.5	1.1	2.0	4.9	0.6	7.2
Unrealized fx loss (included in other,net)	8.6	(59.2)	63.9	(11.6)	1.7	(11.8)	(18.7)
Other (Minority interest expense, Sponsor's fee, severance, franchise taxes)	7.0	4.6	2.2	6.2	20.1	(2.2)	10.8
Disposition adjustments	0.2	-	-	-	0.2	-	-
Subtotal	110.2	54.0	68.4	77.2	309.8	77.7	277.4
Estimated cost savings					-		-
Adjusted EBITDA					309.8		277.4

FY2009 Cash Flow

(\$ millions)	<u>Continuing</u>	<u>Discontinued</u>	<u>Total</u>
Net cash provided by/(used in) operations	69.1	3.8	72.9
Additions PP&E, net	(81.5)	(2.8)	(84.3)
Financing activities			10.5
FX on net cash			(7.6)
Increase/(Decrease) in cash			<u>(8.5)</u>
Cash at beginning of period			72.4
Cash at end of period			63.9
Items of note:			
Net cash cycle working capital decrease/(increase)			28.3
Cash interest			(169.4)
Cash taxes			(18.6)
Revolver at 6/30/09 (\$350 million facility)			36.0
Net Debt at 6/30/09			2,283.4

Catalent®

The logo graphic consists of three overlapping, upward-pointing arrow-like shapes. The top-most shape is dark blue, the middle one is a lighter blue, and the bottom one is purple. They are positioned to the right of the word 'Catalent'.

Reliable Solutions. Inspired Results.™

At the bottom of the slide, there are two horizontal lines. The top one is a solid dark blue line. Below it is a purple line that starts from the left edge and slopes upwards towards the right edge.